Proxi Biotech was founded in 2018, based on research conducted at the Statens Serum Institute in Denmark, with a mission to contribute to global health by developing highly needed vaccines overcoming the urgent threat of antimicrobial resistance.
Our research and technology are led by world-class scientists with a strong passion and track record of turning lab scale research into effective vaccine products.
Proxi Biotech's BACTOVAC platform is a versatile toxoid antigen production technology developed to create and advance novel prophylactic and therapeutic vaccines. Our projects are collaborations with private and public partners in the vaccine development space. We focus in developing and bringing vaccine candidates to preclinical proof-of-concept in relevant animal models and early clinical phase.
We has received numerous national and European non-dilutive grants for a total of ca. 820.000 EUR
TRANSVAC2 - 2022
Evaluation of safety, dose-finding and stability of CDIFFVAC, a superior toxoid-based vaccine against Clostridioides difficile infection
InnoBooster - 2022
Development of a new type of highly potent and safe toxoid-based vaccine against bacterial infections
TRANSVAC2 - 2020
Safety and immunogenicity of a CMS-adjuvanted, newly developed toxoid-based vaccine against C. difficile infection in non-rodent species
Eurostars - 2020
Next generation vaccines for multi-resistant bacteria
EIT Health Headstart - 2020
Next generation vaccines for multi-resistant bacteria
InnoBooster - 2019
Validation of a novel detoxification platform turning bacterial toxins into vaccine antigens
Business Acceleration academy - 2019
New method for creating toxoid-based vaccines
Copyright 2023 Proxi Biotech ApS All Rights Reserved
